

# Triparna Sen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9418814/publications.pdf>

Version: 2024-02-01

39  
papers

3,316  
citations

218677

26  
h-index

302126

39  
g-index

43  
all docs

43  
docs citations

43  
times ranked

4467  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 646-661.  | 9.4  | 555       |
| 2  | Lineage plasticity in cancer: a shared pathway of therapeutic resistance. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 360-371.   | 27.6 | 263       |
| 3  | CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. <i>Frontiers in Oncology</i> , 2020, 10, 1387.  | 2.8  | 247       |
| 4  | SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1823-1835.  | 1.1  | 234       |
| 5  | CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. <i>Cancer Research</i> , 2017, 77, 3870-3884.   | 0.9  | 163       |
| 6  | Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 28575-28587.  | 1.8  | 157       |
| 7  | Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. <i>Cancer Cell</i> , 2021, 39, 1479-1496.e18.   | 16.8 | 155       |
| 8  | Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. <i>Cell Reports</i> , 2020, 33, 108444.   | 6.4  | 118       |
| 9  | Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. <i>Translational Lung Cancer Research</i> , 2018, 7, 50-68.   | 2.8  | 96        |
| 10 | Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NF $\kappa$ B and AP-1 in the human breast cancer cell line MDA-MB-231. <i>Anti-Cancer Drugs</i> , 2010, 21, 632-644.                                       | 1.4  | 94        |
| 11 | STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. <i>Journal of Thoracic Oncology</i> , 2020, 15, 777-791.  | 1.1  | 94        |
| 12 | Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6239-6253.  | 7.0  | 93        |
| 13 | Tim-4 <sup>+</sup> cavity-resident macrophages impair anti-tumor CD8 <sup>+</sup> T cell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9.  | 16.8 | 93        |
| 14 | Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. <i>Life Sciences</i> , 2009, 84, 194-204.  | 4.3  | 90        |
| 15 | Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2152-2163. | 1.1  | 80        |
| 16 | Genome Wide Expression Profiling during Spinal Cord Regeneration Identifies Comprehensive Cellular Responses in Zebrafish. <i>PLoS ONE</i> , 2014, 9, e84212.  | 2.5  | 76        |
| 17 | Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. <i>Oncotarget</i> , 2017, 8, 73419-73432.         | 1.8  | 74        |
| 18 | Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. <i>Cancer Discovery</i> , 2021, 11, 3028-3047.  | 9.4  | 66        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Targeted Therapies and Biomarkers in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 741.  | 2.8  | 65        |
| 20 | MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 3485.  | 12.8 | 54        |
| 21 | Fibronectin induces matrix metalloproteinase-9 (MMP-9) in human laryngeal carcinoma cells by involving multiple signaling pathways. <i>Biochimie</i> , 2010, 92, 1422-1434.   | 2.6  | 51        |
| 22 | The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 1293-1303.  | 0.9  | 49        |
| 23 | WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. <i>Cell Reports</i> , 2022, 39, 110814.   | 6.4  | 43        |
| 24 | Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity. <i>Tumor Biology</i> , 2011, 32, 129-138.   | 1.8  | 42        |
| 25 | Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). <i>Molecular and Cellular Biochemistry</i> , 2010, 336, 65-74.   | 3.1  | 35        |
| 26 | All-trans retinoic acid (ATRA) downregulated MMP-9 by modulating its regulatory molecules. <i>Cell Adhesion and Migration</i> , 2010, 4, 409-418.   | 2.7  | 33        |
| 27 | Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1014-1031. | 1.1  | 31        |
| 28 | Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 170.                                  | 17.0 | 26        |
| 29 | <i>Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 3214-3229.  | 9.4  | 24        |
| 30 | Laminin induces matrix metalloproteinase-9 expression and activation in human cervical cancer cell line (SiHa). <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 347-357.   | 2.5  | 23        |
| 31 | Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy. <i>Cancer Research</i> , 2022, 82, 472-483.  | 0.9  | 18        |
| 32 | Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. <i>Nature Communications</i> , 2022, 13, 2144.   | 12.8 | 18        |
| 33 | Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 346-357.   | 7.0  | 14        |
| 34 | MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. <i>IScience</i> , 2021, 24, 103224.   | 4.1  | 13        |
| 35 | Identifying and targeting the Achilles heel of a recalcitrant cancer. <i>Science Translational Medicine</i> , 2021, 13, .   | 12.4 | 5         |
| 36 | Culture of K562 human myeloid leukemia cells in presence of fibronectin expresses and secretes MMP-9 in serum-free culture medium. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 3, 288-302.                    | 0.5  | 5         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | An optimized NGS sample preparation protocol for in vitro CRISPR screens. STAR Protocols, 2021, 2, 100390.  | 1.2 | 2         |
| 38 | Should WEE1/CHK1 be on the FAM122A list?. Molecular Cell, 2020, 80, 377-378.  | 9.7 | 1         |
| 39 | Focal adhesion kinase induces matrix metalloproteinase-2 by involving $\beta$ 5 $\gamma$ 1-mediated signaling in breast cancer cell, MCF-7. Acta Medica International, 2015, 2, 29. | 0.2 | 0         |